MUSICC is proud to announce that enrolment has now been completed for the project’s first human challenge study, COV-CHIM02. This achievement marks a major milestone in the progression of the project.
The study aims to improve understanding of COVID-19 and support the development of future studies. Human challenge studies play an important role in infectious disease research by allowing scientists to study infections in carefully controlled settings, under close medical supervision and with extensive ethical oversight.
Researchers delivered the COV-CHIM02 study through collaboration between multiple UK research institutions, within the MUSICC consortium. Under strict medical conditions, researchers deliberately infected volunteers with the SARS-CoV-2 virus. This is the virus that causes the disease COVID-19; the study used a sub-variant of the Omicron variant named BA.5.
Human challenge studies allow MUSICC to gather crucial data on coronaviruses. Credit: Thomas Angus/Imperial College London
The aim of the study was to establish infection in a defined proportion of volunteers, while identifying the optimal conditions under which infections occurs. This included understanding the interaction between the virus dose and participants’ pre-existing antibody levels. This will help researchers to better understand how prior immunity influences infection.
Clinical teams closely monitored volunteers throughout the study, ensuring their safety and wellbeing was the top priority at all times.
Participants in human challenge studies are closely monitored by medical staff throughout. Credit: Thomas Angus/Imperial College London
With recruitment now closed, the study will not enrol any new volunteers. Researchers will continue to follow up with existing participants in line with the study plan. Other work in MUSICC is still ongoing.
The COV-CHIM02 study is an important step for the MUSICC project as it delivers many benefits beyond its scientific results. The study’s successful delivery supports the design of future studies and refines methods for conducting them safely and effectively. Through COV-CHIM02, research teams across the consortium gained training and practical experience that will support the delivery of future MUSICC studies.
This work also contributes to wider scientific efforts beyond MUSICC, helping researchers plan robust studies that can be delivered efficiently in response to future infectious disease threats.
The study team conducted all stages of COV-CHIM02 under independent ethical approval and ongoing safety monitoring. Volunteer wellbeing is central to human challenge studies and was closely observed throughout.
Participant safety and wellbeing is a top priority of any human challenge study. Credit: Thomas Angus/Imperial College
Follow-up work with study volunteers will continue to monitor longer-term safety and health effects. Volunteers only leave study quarantine once they are no longer infectious from exposure to the study virus.
The study team are sharing samples and data with MUSICC consortium partners to enable further research, including work to identify potential correlates of protection.
Researchers will analyse the data from the COV-CHIM02 study and share the findings through peer-reviewed publications in due course.
Progress in infectious disease research depends on sustained effort, collaboration and public trust.
MUSICC would like to take this opportunity to thank our study participants and partners, without which this study would not have been possible.
MUSICC will continue to build on this work in advancing ethical models for human challenge studies and laying the groundwork for the next generation of vaccines.
